%D8%AA%D9%8A%D9%85%D9%88%D9%84%D9%88%D9%84%D8%AA%DB%8C%D9%85%D9%88%D9%84%D9%88%D9%84TimololCategory:TimololTimololTimololTimololTimolol%D8%AA%DB%8C%D9%85%D9%88%D9%84%D9%88%D9%84TimololiTimololTimolol%D4%B9%D5%AB%D5%B4%D5%B8%D5%AC%D5%B8%D5%ACTimololo%E3%83%81%E3%83%A2%E3%83%AD%E3%83%BC%E3%83%AB%ED%8B%B0%EB%AA%A8%EB%A1%A4%D0%A2%D0%B8%D0%BC%D0%BE%D0%BB%D0%BE%D0%BBTimolol%E0%AC%9F%E0%AC%BE%E0%AC%87%E0%AC%AE%E0%AD%8B%E0%AC%B2%E0%AD%8B%E0%AC%B2TymololTimolol%D0%A2%D0%B8%D0%BC%D0%BE%D0%BB%D0%BE%D0%BBTimololTimolol%D0%A2%D0%B8%D0%BC%D0%BE%D0%BB%D0%BE%D0%BBTimololQ413994
about
sameAs
P3364
Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed CombinationMK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus TravoprostStudy of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular HypertensionBeta Blocker for Chronic Wound HealingSafety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionPatient Preference Comparison of AZARGA Versus COSOPT in Patients With GlaucomaTravacom Post Marketing Surveillance StudyEffect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First ChoiceA Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical SettingAdherence Assessment With Travalert Dosing AidTravoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular HypertensionEarlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for GlaucomaSafety and Efficacy Study of DuoTrav APS Versus DuoTravAfrican Glaucoma Laser TrialA Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 StudyA Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 StudyComparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension SubjectsSafety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) ReductionStudy of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular HypertensionA Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With GlaucomaEfficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension GlaucomaPatient Preference Comparison of AZARGA Versus COSOPTSafety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on TimololFixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular HypertensionAR-12286 in Combination With LatanoprostEfficacy of Changing to DUOTRAV® From Prior TherapyTafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against MonotherapiesSafety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionSafety and Efficacy of Changing to DuoTrav From Prior TherapyRandomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open WoundsPeripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography StudyComparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood FlowSafety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension (2011-01-31)Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension (2005-05-31)
P4844
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.Functional group contributions to drug-receptor interactions.Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.New approaches to antiglaucoma therapy.Approaches to vasodilating/beta-adrenergic blocking agents: examples of the dihydrolutidine type.Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene.High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates.Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.Cheminformatic models to predict binding affinities to human serum albumin.QSAR model for drug human oral bioavailability.Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomasAcetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranesBinding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship modelsUrinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activitiesSurface activity profiling of drugs applied to the prediction of blood-brain barrier permeabilityAqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
(S)-(−)-Timolol
@de
(S)-(−)-timolol
@en
(S)-(−)-timolol
@fr
(S)-(−)-tymolol
@pl
Timolol
@bs
Timolol
@es
Timolol
@hu
Timolol
@nl
Timolol
@sh
Timolol
@sr
type
label
(S)-(−)-Timolol
@de
(S)-(−)-timolol
@en
(S)-(−)-timolol
@fr
(S)-(−)-tymolol
@pl
Timolol
@bs
Timolol
@es
Timolol
@hu
Timolol
@nl
Timolol
@sh
Timolol
@sr
altLabel
(-)-S-Timolol
@cy
(-)-S-timolol
@en
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
@cy
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
@en
ATCvet kod QC07AA06
@sr
ATCvet kod QS01ED01
@sr
Betimol
@sr
Blocadren
@sr
C13H24N4O3S
@it
NYO142
@en
prefLabel
(S)-(−)-Timolol
@de
(S)-(−)-timolol
@en
(S)-(−)-timolol
@fr
(S)-(−)-tymolol
@pl
Timolol
@bs
Timolol
@es
Timolol
@hu
Timolol
@nl
Timolol
@sh
Timolol
@sr